INO Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

$7.25  +0.33 (4.77%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/21/2001
Outstanding shares:  210,385,877
Average volume:  4,317,615
Market cap:   $1,455,870,269
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45773H201
ISIN:        US45773H2013
Sedol:      BN5H5K1
Valuation   (See tab for details)
PE ratio:   -6.90
PB ratio:   3.36
PS ratio:   223.42
Return on equity:   -48.74%
Net income %:   -3,392.30%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy